by Richard Tomkins
Washington (UPI) Sep 26, 2017
Humanetics Corporation is to develop solid-dosage formulations of BIO 300, a drug to mitigate the toxicities of exposure to radiation.
The drug, administered orally, is in clinical development by the Minnesota-based firm and is aimed for deployment to military personnel and first responders.
Humanetics' work on dosage is the result of a $3.8 million grant from the U.S. Department of Defense's Congressionally Directed Medical Research Programs, Peer-Reviewed Medical Research Program.
"In light of increasing geopolitical pressures regarding the potential use of radiological or nuclear weaponry, the protection of our armed forces from radiation exposure and enabling them to operate in areas of possible concern is a strategic imperative," said Dr. Michael Kaytor, vice president of Research and Development at Humanetics, said in a news release.
BIO 300's protective properties were originally discovered by researchers within the Department of Defense. This technology was licensed to Humanetics Corporation, which is leading BIO 300's advanced development.
In parallel to BIO 300's development for use by the military, Humanetics is evaluating the drug in a Phase Ib/IIa clinical trial to determine its potential to reduce normal tissue toxicities associated with cancer radiotherapy.
"We are very excited that the DoD continues to support BIO 300 as a drug that can be used to protect military personnel and civilians at risk of radiation exposure," said Ronald J. Zenk, chief executive officer of Humanetics. "We are constantly working toward making this therapy available in ways that support the many disparate populations at risk of radiation exposure."
Houston TX (SPX) Sep 21, 2017
While people protect their eyes from the sun's radiation during a solar eclipse, NASA's Human Research Program (HRP) is working to protect the whole human body from radiation in space. Space radiation is dangerous and one of the primary health risks for astronauts. "Determining astronaut health consequences following radiation exposure involve very complex processes," said Tony Slaba, Ph.D ... read more
Space Technology News - Applications and Research
|The content herein, unless otherwise known to be public domain, are Copyright 1995-2017 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement|